ARS Pharmaceuticals
SPRY
92 hedge funds and large institutions have $369M invested in ARS Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 32 increasing their positions, 19 reducing their positions, and 27 closing their positions.
146% more call options, than puts
Call options by funds: $7.92M | Put options by funds: $3.22M
68% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 19
15% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 27
6% more capital invested
Capital invested by funds: $348M → $369M (+$21.3M)
3% more funds holding
Funds holding: 89 → 92 (+3)
1.52% more ownership
Funds ownership: 56.59% → 58.11% (+1.5%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.62M |
| 2 |
Millennium Management
New York
|
+$6.34M |
| 3 |
SCM
Sio Capital Management
New York
|
+$3.62M |
| 4 |
Two Sigma Investments
New York
|
+$3.2M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$3.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$9.44M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$4.55M |
| 3 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$3.21M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.83M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.72M |
SPRY Hedge Fund Activity: Q2 2023 in Review
92 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q2 2023, worth a combined $369M — up 6.1% from $348M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new SPRY positions and 27 closed out — a net gain of 4 holders — while 32 added to existing stakes and 19 trimmed.
The largest buyer was BlackRock, adding an estimated $7.62M. The largest seller was K2 Principal Fund, cutting an estimated $9.44M.
- 92 institutional investors held ARS Pharmaceuticals (SPRY) as of Q2 2023, up from 89 in Q1 2023.
- Funds reported $369M of ARS Pharmaceuticals stock for Q2 2023, up 6.1% quarter-over-quarter.
- 31 funds opened new ARS Pharmaceuticals positions in Q2 2023 and 27 closed out, a net change of +4 holders.
- The largest ARS Pharmaceuticals buyer in Q2 2023 was BlackRock, an estimated $7.62M added.
- The largest ARS Pharmaceuticals seller in Q2 2023 was K2 Principal Fund, an estimated $9.44M sold.
Based on aggregated 13F filings for Q2 2023.